Five-year clinical experience with the Omniscience cardiac valve

Area of Science:

• Cardiovascular Surgery
• Biomaterials Science
• Clinical Outcomes Research

Background:

• The Omniscience cardiac valve prosthesis is a device used in heart valve replacement surgeries.
• Patient populations undergoing cardiac valve replacement often have complex medical histories, including prior surgeries and advanced heart disease.

Purpose of the Study:

• To evaluate the clinical performance and safety of the Omniscience cardiac valve prosthesis in a large patient cohort.
• To assess long-term outcomes, including survival rates, functional improvement, and hematological parameters, following implantation of the Omniscience prosthesis.

Main Methods:

• A retrospective analysis of clinical data from 326 patients who received the Omniscience cardiac valve prosthesis (sizes 19-31 mm).
• Data collected over a five-year period, encompassing 650 patient-years, with 96% accountability.
• Inclusion criteria involved patients undergoing aortic valve replacement (AVR), mitral valve replacement (MVR), or double-valve replacement.

Main Results:

• Five-year actuarial thrombus-free rates were 96% for AVR and 95% for MVR.
• Postoperatively, 89% of patients were in New York Heart Association (NYHA) Functional Class I or II, with 84% improving by at least one class.
• High proportions of patients exhibited normal postoperative hematological values (RBC 94%, hematocrit 88%, hemoglobin 93%), with 98% free from clinical anemia.
• Actuarial five-year survival rates were comparable for AVR (82%) and MVR (80%).

Conclusions:

• The Omniscience cardiac valve prosthesis demonstrates satisfactory safety and performance in both aortic and mitral valve replacement procedures.
• The prosthesis is associated with significant functional improvement and favorable hematological profiles in the majority of patients.
• Long-term survival rates indicate the device's reliability and suitability for widespread clinical use in cardiac valve replacement.